Table 1 Clinical and biochemical data of examined patients
From: AGLR is a novel index for the prognosis of hepatocellular carcinoma patients: a retrospective study
Parameter | Training cohort | Validation cohort | p value |
|---|---|---|---|
(n = 248) | (n = 247) | ||
Basic information | |||
Age (years) | 49.33 ± 11.35 | 50.96 ± 11.80 | 0.119 |
Gender: n (%) | |||
Female | 29 (11.7) | 34 (13.8) | 0.489 |
Male | 219 (88.3) | 213 (86.2) | |
Family history: n (%) | |||
No | 216 (87.0) | 219 (88.7) | 0.435 |
Yes | 32 (13.0) | 28 (11.3) | |
Drinking: n (%) | |||
No | 140 (56.5) | 133 (53.8) | 0.560 |
Yes | 108 (43.5) | 114 (46.2) | |
Smoking: n (%) | |||
No | 148 (59.7) | 152 (61.5) | 0.577 |
Yes | 100 (40.3) | 95 (38.5) | |
HBsAg: n (%) | |||
Negative | 41 (16.5) | 34 (13.8) | 0.391 |
Positive | 207 (83.5) | 213 (86.2) | |
Minimally invasive surgery: n (%) | |||
No | 184 (74.2) | 180 (72.9) | 0.739 |
Yes | 64 (25.8) | 67 (27.1) | |
Lab check data | |||
WBC (× 109/L) | 6.04 ± 2.01 | 6.39 ± 2.20 | 0.061 |
NEUT (× 109/L) | 3.65 ± 1.71 | 3.92 ± 1.73 | 0.081 |
LYMPH (× 109/L) | 1.64 ± 0.57 | 1.73 ± 0.65 | 0.105 |
Platelets (× 109/L) | 173.96 ± 75.18 | 181.23 ± 79.27 | 0.096 |
Albumin (g/L) | 39.07 ± 4.59 | 39.65 ± 4.66 | 0.220 |
Globulin (g/L) | 31.01 ± 5.80 | 30.35 ± 6.18 | 0.215 |
TBIL (μmol/L) | 15.91 ± 14.33 | 16.45 ± 16.07 | 0.747 |
DBIL (μmol/L) | 6.33 ± 12.38 | 6.92 ± 13.17 | 0.689 |
ALT (U/L) | 45.12 ± 42.93 | 51.08 ± 46.33 | 0.783 |
AST (U/L) | 49.98 ± 48.83 | 51.91 ± 57.49 | 0.697 |
ALP (U/L) | 95.69 ± 65.26 | 92.29 ± 42.60 | 0.493 |
GGT (U/L): median, range | 67.62, 10.7–335.1 | 72.19, 10.0–351.76 | 0.854 |
AGLR level: median, range | 90.63, 19.43–441.72 | 88.83, 16.07–462.16 | 0.521 |
AFP (ng/mL): median, range | 246.7, 0.20–32,800 | 220.7, 0.60–25,410 | 0.363 |
Pathological features | |||
Cirrhosis: n (%) | |||
No | 24 (10.0) | 13 (5.3) | 0.062 |
Yes | 224 (90.0) | 234 (94.7) | |
Tumor size (cm) | 7.81 ± 4.68 | 7.12 ± 4.11 | 0.085 |
Tumor number: n (%) | |||
Single | 190 (76.6) | 188 (76.1) | 0.896 |
Multiple | 58 (23.4) | 59 (23.9) | |
TNM stage: n (%) | |||
I-II | 136 (54.8) | 124 (50.2) | 0.302 |
III-IV | 112 (45.2) | 123 (49.8) | |
MVI: n (%) | |||
No | 201 (81.0) | 188 (76.1) | 0.181 |
Yes | 47 (19.0) | 59 (23.9) | |
Recurrence: n (%) | |||
No | 158 (63.7) | 148 (59.9) | 0.385 |
Yes | 90 (36.3) | 99 (40.1) |